# SynthLife â€” Autonomous Protein Design Intelligence

*Design any protein. For any purpose. In hours, not years.*

---

## Executive Summary

SynthLife is the autonomous AI platform for protein design. While AlphaFold predicted protein structures, we go further â€” we *design* novel proteins to exact specifications for any application: therapeutics, materials, agriculture, industrial enzymes. The synthetic biology market is projected to reach $85B by 2030, and protein engineering is the core technology that makes it all possible. We're building the platform that lets any company design custom proteins without a PhD in structural biology.

**The Ask:** $20M Seed to build the design engine and launch with 10 biotech partners

---

## The Problem

### Proteins Are Everything â€” But Designing Them Is Hell

Proteins are the molecular machines of life:
- **Therapeutics:** Antibodies, enzymes, gene therapies
- **Materials:** Spider silk, bio-plastics, self-healing materials
- **Agriculture:** Disease-resistant crops, nitrogen fixation
- **Industrial:** Enzymes for biofuel, food processing, carbon capture

**The design challenge is brutal:**

| Traditional Approach | Reality |
|---------------------|---------|
| Directed evolution | 2-5 years, $10M+, mostly fails |
| Rational design | Requires expert teams, low success rate |
| Computational design | Fragmented tools, no integration |
| AlphaFold | Predicts structure, doesn't *design* |

### The Gap in the Market

AlphaFold revolutionized protein structure *prediction*. But prediction isn't design:

- **Prediction:** "Here's what this existing protein looks like"
- **Design:** "Create me a protein that binds to X, is stable at Y temperature, and doesn't trigger immune response"

This is like the difference between Google Translate and GPT-4. One maps; the other creates.

### Who Feels This Pain?

1. **Pharma/Biotech** â€” $50B+ annual R&D spend, 90% failure rate
2. **Materials companies** â€” Racing to replace petroleum-based plastics
3. **Agricultural giants** â€” Climate change demands new crop solutions
4. **Industrial biotech** â€” Enzymes for green chemistry worth $15B/year
5. **Academic labs** â€” Brilliant ideas, no tools to execute

---

## The Solution

### SynthLife: The Protein Design Operating System

We're building the first end-to-end autonomous platform for protein design:

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                         SYNTHLIFE                                â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚  â”‚  Natural  â”‚â”€â”€â”€â–¶â”‚  Design   â”‚â”€â”€â”€â–¶â”‚ Simulate  â”‚â”€â”€â”€â–¶â”‚ Lab    â”‚ â”‚
â”‚  â”‚  Language â”‚    â”‚  Engine   â”‚    â”‚ & Verify  â”‚    â”‚ Recipe â”‚ â”‚
â”‚  â”‚  Spec     â”‚    â”‚  (AI)     â”‚    â”‚  (AI)     â”‚    â”‚        â”‚ â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                    DESIGN CAPABILITIES                          â”‚
â”‚  â€¢ De novo protein design        â€¢ Binding affinity optimizationâ”‚
â”‚  â€¢ Enzyme engineering            â€¢ Stability engineering        â”‚
â”‚  â€¢ Antibody design               â€¢ Immunogenicity reduction     â”‚
â”‚  â€¢ Protein-protein interfaces    â€¢ Expression optimization      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Core Features

#### 1. Natural Language Protein Specification
```
User: "Design a protein that binds to PD-1 with Kd < 1nM,
       stable at 37Â°C for 30 days, and has low immunogenicity
       for human therapeutic use"

SynthLife: Generates 50 candidate designs with predicted
           properties, ranked by confidence
```

#### 2. Multi-Objective Design Engine
- **Binding:** Design proteins that bind specific targets
- **Stability:** Thermal, pH, and shelf-life optimization
- **Expression:** Designs optimized for E. coli, yeast, or mammalian cells
- **Safety:** Immunogenicity and toxicity prediction
- **Manufacturability:** Scalable production pathways

#### 3. In-Silico Validation Suite
- Molecular dynamics simulation (automated)
- Binding affinity prediction (validated to 0.5 kcal/mol accuracy)
- Expression probability scoring
- Patent landscape analysis (freedom to operate)

#### 4. Lab Integration
- Automated DNA synthesis ordering
- Protocol generation for expression/purification
- Integration with robotic labs (Emerald Cloud, Strateos)
- Experimental feedback loop for model improvement

---

## Market Opportunity

### The Synthetic Biology Explosion

| Segment | 2024 | 2030 | CAGR |
|---------|------|------|------|
| Synthetic Biology Total | $18B | $85B | 29% |
| Protein Therapeutics | $42B | $90B | 13% |
| Industrial Enzymes | $7B | $15B | 11% |
| Bio-based Materials | $12B | $35B | 19% |
| Agricultural Biotech | $25B | $55B | 14% |

**Total Addressable Market:** $280B+ by 2030

### Our Wedge: Therapeutic Antibodies

The antibody market alone is $200B+. Current design takes 2-3 years and costs $50M+ per candidate. We can compress this to weeks and $500K.

**SynthLife's Market Capture:**

| Year | Revenue | Customers | Proteins Designed |
|------|---------|-----------|-------------------|
| 2026 | $2M | 15 | 500 |
| 2027 | $12M | 60 | 3,000 |
| 2028 | $45M | 200 | 15,000 |
| 2029 | $120M | 500 | 50,000 |
| 2030 | $300M | 1,200 | 150,000 |

---

## Business Model

### Three Revenue Streams

#### 1. Platform Subscription (60% of revenue)
| Tier | Price | Features |
|------|-------|----------|
| Starter | $5K/mo | 50 designs/mo, basic validation |
| Professional | $25K/mo | 500 designs/mo, full simulation |
| Enterprise | $100K+/mo | Unlimited, dedicated compute, custom models |

#### 2. Success Fees (25% of revenue)
- 1-2% royalty on therapeutics that reach clinical trials
- $50K-500K milestone payments for successful designs
- Performance bonuses for exceeding binding/stability specs

#### 3. Data & Insights (15% of revenue)
- Anonymized design intelligence reports
- Custom model training on proprietary data
- Consulting for complex design challenges

### Unit Economics

| Metric | Value |
|--------|-------|
| Average Contract Value | $180K/year |
| Gross Margin | 85% |
| CAC | $45K |
| LTV | $540K (3-year avg retention) |
| LTV:CAC | 12:1 |

---

## Technology Deep Dive

### The SynthLife AI Stack

#### Foundation: SynthGPT-1
Our proprietary protein language model trained on:
- **500M+ protein sequences** (UniProt, metagenomics)
- **200M+ protein structures** (AlphaFold DB, PDB)
- **10M+ experimental data points** (binding, expression, stability)
- **1M+ failed designs** (learning from what doesn't work)

**Key innovations:**
- Multi-task learning across design objectives
- Reinforcement learning from experimental feedback
- Uncertainty quantification (we tell you when we're not confident)

#### Design Engine: ProteinDiffusion
Diffusion models for de novo protein generation:
- Generate novel folds not seen in nature
- Conditional generation on specific properties
- Iterative refinement with physics-based scoring

#### Validation: MolecularSim
GPU-accelerated molecular dynamics:
- 1000x faster than traditional MD
- Automated binding free energy calculations
- Aggregation and stability prediction

### Competitive Moat

| Capability | SynthLife | Competitors |
|------------|-----------|-------------|
| End-to-end design | âœ… | Fragmented tools |
| Natural language spec | âœ… | Code/GUI only |
| Multi-objective optimization | âœ… | Single objective |
| Experimental feedback loop | âœ… | Static models |
| Manufacturing integration | âœ… | Design only |
| IP/patent analysis | âœ… | Not included |

---

## Competition & Differentiation

### Landscape

| Company | Focus | Limitation |
|---------|-------|------------|
| **Generate Biomedicines** | Therapeutic proteins | Narrow focus, pharma only |
| **Absci** | Antibody discovery | Antibodies only, wet lab heavy |
| **Cradle** | Protein engineering | Early stage, limited capabilities |
| **EvolutionaryScale** | ESM models | Models only, no platform |
| **Insilico Medicine** | Drug discovery | Small molecules, not proteins |

### Our Differentiation

1. **Full-stack platform** â€” Not just models, complete workflow
2. **Any protein, any purpose** â€” Not limited to therapeutics
3. **Natural language interface** â€” Democratizes access
4. **Feedback loop** â€” Models improve with every experiment
5. **Manufacturing integration** â€” From design to production

---

## Traction & Validation

### Early Partnerships

| Partner | Use Case | Status |
|---------|----------|--------|
| Top-5 Pharma | Antibody optimization | LOI signed, $500K pilot |
| Materials Startup | Bio-silk protein | Designing, first batch in lab |
| Agricultural Co | Nitrogen fixation enzyme | Research collaboration |
| Academic Medical Center | Rare disease therapeutic | NIH grant co-application |

### Technical Validation

- **Binding accuracy:** 0.5 kcal/mol RMSE (state of the art)
- **Design success rate:** 35% hit rate (vs. 5% industry standard)
- **Expression prediction:** 80% accuracy for E. coli
- **Speed:** 500 designs/hour vs. weeks for traditional methods

---

## Go-to-Market Strategy

### Phase 1: Pharma Beachhead (2026)
**Target:** Mid-size biotech companies (50-500 employees)
- They need design capabilities but can't afford $50M internal platforms
- Faster decision cycles than Big Pharma
- Willing to try new tools for competitive advantage

**Channels:**
- Direct sales to VP R&D / CSO
- Conference presence (BIO, JPM Healthcare)
- Academic publication pipeline
- Strategic partnerships

### Phase 2: Platform Expansion (2027)
**Expand to:**
- Industrial biotech (enzymes, biomanufacturing)
- Materials companies (bio-based alternatives)
- Agricultural biotech

### Phase 3: Ecosystem (2028+)
**Build the platform economy:**
- API for other biotech tools
- Marketplace for design templates
- Certified lab partner network
- Training and certification program

---

## Team

### Why We Win

#### Dr. Sarah Chen â€” CEO
- PhD Computational Biology, Stanford
- Former Head of Protein Engineering, Genentech
- Led team that designed 3 FDA-approved antibodies
- 50+ publications, 15 patents

#### Dr. Marcus Williams â€” CTO
- PhD Machine Learning, MIT
- Former Research Scientist, DeepMind (AlphaFold team)
- Co-author on AlphaFold2 paper
- Built ML infrastructure at 2 biotech unicorns

#### Dr. Priya Patel â€” Chief Science Officer
- PhD Structural Biology, Cambridge
- Former VP Discovery, Regeneron
- 20 years protein therapeutics experience
- Discovered 2 blockbuster antibody drugs ($5B+ revenue)

#### James Morrison â€” COO
- MBA Harvard Business School
- Former McKinsey Partner, healthcare practice
- Built operations at Moderna during scale-up
- Deep biotech investor network

### Advisory Board
- David Baker (Institute for Protein Design)
- Daphne Koller (Insitro CEO)
- John Maraganore (former Alnylam CEO)
- George Church (Harvard, synthetic biology pioneer)

---

## Financials

### Use of Funds ($20M Seed)

| Category | Allocation | Purpose |
|----------|------------|---------|
| R&D / Engineering | $10M | Model development, platform build |
| Compute Infrastructure | $4M | GPU clusters for training/inference |
| Wet Lab Validation | $3M | Experimental validation partnerships |
| Go-to-Market | $2M | Sales, marketing, partnerships |
| Operations | $1M | Legal, admin, facilities |

### Projected Financials

| Year | Revenue | Gross Profit | Net Income | Headcount |
|------|---------|--------------|------------|-----------|
| 2026 | $2M | $1.6M | -$12M | 35 |
| 2027 | $12M | $10M | -$8M | 65 |
| 2028 | $45M | $38M | $5M | 120 |
| 2029 | $120M | $102M | $35M | 200 |
| 2030 | $300M | $255M | $100M | 350 |

### Key Assumptions
- 40% YoY customer growth after 2027
- 85% gross margin maintained
- R&D at 35% of revenue long-term
- Profitability in Year 3

---

## Risk Factors & Mitigations

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| Technical: Models don't generalize | Medium | High | Diverse training data, experimental feedback |
| Competition from Big Tech | Medium | Medium | Speed to market, domain expertise, data moat |
| Regulatory uncertainty | Low | Medium | Engage FDA early, conservative claims |
| Talent acquisition | Medium | Medium | Equity packages, mission-driven culture |
| Long sales cycles | High | Medium | Land-and-expand, POC programs |

---

## The Investment Thesis

### Why SynthLife Wins

1. **Perfect Timing:** AlphaFold proved AI can understand proteins. Now it's time to design them.

2. **Massive Market:** $280B TAM across therapeutics, materials, agriculture, industrial â€” we're the picks and shovels.

3. **Technical Moat:** Proprietary models + experimental feedback loop = compounding advantage.

4. **World-Class Team:** AlphaFold DNA, Genentech experience, proven operators.

5. **Clear Path to $1B+:** Platform economics with expansion into multiple verticals.

### Comparable Exits

| Company | Sector | Exit Value | Revenue at Exit |
|---------|--------|------------|-----------------|
| Grail | Cancer screening | $8B | $100M |
| Recursion | Drug discovery | $6B (market cap) | $200M |
| Zymergen | Biomanufacturing | $3B (peak) | $50M |
| Generate Biomedicines | Protein design | $1.5B (valuation) | Pre-revenue |

---

## The Ask

**$20M Seed Round**

- Lead: $12M
- Strategic co-investors: $8M (pharma CVCs preferred)
- Valuation: $100M pre-money

**What we deliver:**
- SynthLife platform v1.0 (12 months)
- 10 paying biotech customers
- 3 therapeutic programs in pipeline
- Series A ready with $5M ARR trajectory

---

## Contact

**SynthLife, Inc.**

*Design any protein. For any purpose. In hours, not years.*

ğŸ“§ founders@synthlife.ai
ğŸŒ www.synthlife.ai
ğŸ“ South San Francisco, CA

---

*"The 20th century was defined by chemistry. The 21st century will be defined by biology. SynthLife is the platform that makes that future possible."*

â€” Dr. Sarah Chen, CEO
